Efficacy, pharmacokinetics, safety, and tolerability of Flebogamma 10% DIF, a high-purity human intravenous immunoglobulin, in primary immunodeficiency.
BACKGROUND
Flebogamma 10% DIF represents an evolution of intravenous immune globulin from the previous 5% product to be administered at higher rates and with smaller infusion volumes. Pathogen safety is enhanced by the combination of multiple methods with different mechanisms of action.


OBJECTIVE
The objective of this study as to evaluate the efficacy, pharmacokinetics, and safety of Flebogamma 10% DIF for immunoglobulin replacement therapy in primary immunodeficiency diseases (PIDD).


METHODS
Flebogamma 10% DIF was administered to 46 subjects with well-defined PIDD at a dose of 300-600 mg/kg every 21-28 days for 12 months.


RESULTS
Serious bacterial infection rate was 0.025/subject/year. Half-life in serum of the administered IgG was approximately 35 days. No serious treatment-related adverse event (AE) occurred in any patient. Most of the potentially treatment-related AEs occurred during the infusion, accounting for 20% of the 601 infusions administered.


CONCLUSIONS
Flebogamma 10% DIF is efficacious and safe, has adequate pharmacokinetic properties, and is well-tolerated for the treatment of PIDD.
Berger
Melvin
M
Case Western Reserve University, Cleveland, OH, USA.
Pinciaro
Paul J
PJ
Althaus
Arthur
A
Ballow
Mark
M
Chouksey
Akhilesh
A
Moy
James
J
Ochs
Hans
H
Stein
Mark
M
D000293:Adolescent; D000328:Adult; D000368:Aged; D001424:Bacterial Infections / Q000209:etiology; D002648:Child; D054796:Drug Dosage Calculations; D004341:Drug Evaluation; D005260:Female; D006207:Half-Life; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D007153:Immunologic Deficiency Syndromes / Q000276:immunology / Q000628:therapy*; D008297:Male; D008875:Middle Aged
D016756:Immunoglobulins, Intravenous